Rational Pharmacotherapy in Cardiology

Scope & Guideline

Unlocking the Future of Cardiac Care with Rational Approaches

Introduction

Explore the comprehensive scope of Rational Pharmacotherapy in Cardiology through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Rational Pharmacotherapy in Cardiology in depth and align your research initiatives with current academic trends.
LanguageMulti-Language
ISSN1819-6446
PublisherSOC CARDIOLOGY RUSSIAN FEDERAT
Support Open AccessYes
CountryRussian Federation
TypeJournal
Convergefrom 2012 to 2024
AbbreviationRATION PHARMACOTHER / Ration. Pharmacother. Cardiol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPETROVERIGSKII PEREULOK 10, MOSCOW 101990, RUSSIA

Aims and Scopes

The journal 'Rational Pharmacotherapy in Cardiology' primarily focuses on the intersection of pharmacotherapy and cardiovascular diseases, emphasizing evidence-based practices and innovative treatment strategies. It aims to provide insights into the pharmacological management of various cardiac conditions, while also addressing the complexities of comorbidities and patient adherence.
  1. Pharmacotherapy in Cardiovascular Diseases:
    The journal publishes extensive research on the pharmacological management of cardiovascular diseases, including studies on the efficacy and safety of various drug therapies, including anticoagulants, antihypertensives, and lipid-lowering agents.
  2. Comorbidities and Cardiovascular Health:
    A significant focus is placed on the management of cardiovascular diseases in the context of comorbid conditions such as diabetes, chronic kidney disease, and obesity, exploring how these factors influence treatment outcomes.
  3. Clinical Outcomes and Prognostic Factors:
    Research often emphasizes the prognostic significance of various clinical factors, laboratory markers, and biomarkers in predicting outcomes for patients with cardiovascular diseases, thereby aiding in risk stratification and personalized medicine.
  4. Innovative Therapeutic Approaches:
    The journal highlights novel treatment strategies, including the use of new drug classes, combination therapies, and personalized medicine approaches, while also addressing adherence to therapy and patient-centered care.
  5. Epidemiological and Observational Studies:
    There is a strong emphasis on epidemiological studies that investigate the prevalence and impact of cardiovascular diseases, treatment patterns, and adherence among diverse populations.
The journal has seen a rise in interest in several emerging themes, reflecting current trends and advancements in cardiology and pharmacotherapy. These themes highlight the dynamic nature of research in this field.
  1. Pharmacogenomics and Personalized Medicine:
    Recent publications emphasize the role of genetic factors in drug response, particularly in anticoagulant therapy, indicating a growing interest in personalized medicine tailored to individual patient profiles.
  2. Impact of COVID-19 on Cardiovascular Health:
    There is an increased focus on the cardiovascular implications of COVID-19, including its effects on existing heart conditions and the management of patients post-infection.
  3. Integrative Approaches to Cardiovascular Care:
    Studies exploring integrative and multidisciplinary approaches to cardiovascular care are on the rise, highlighting the importance of collaboration among specialists in managing complex patient cases.
  4. Chronic Disease Management and Patient Adherence:
    Research focusing on adherence to treatment regimens, particularly in the context of chronic diseases, is increasingly relevant as it impacts overall treatment effectiveness and patient outcomes.
  5. Innovative Biomarkers and Diagnostic Tools:
    The journal is publishing more studies examining novel biomarkers and diagnostic techniques that enhance the understanding and management of cardiovascular diseases.

Declining or Waning

While the journal continues to thrive in many areas, certain themes appear to be waning, reflecting shifts in research priorities and clinical practice. These declining scopes indicate a need for adaptation in focus areas.
  1. Traditional Antiarrhythmic Therapies:
    Research on classic antiarrhythmic drugs has seen a decrease, possibly due to the emergence of newer therapies and a shift towards more personalized approaches in managing arrhythmias.
  2. Generalized Lipid Management Strategies:
    There is a noticeable decline in studies focused on traditional lipid management protocols, as more emphasis is placed on innovative therapies like PCSK9 inhibitors and inclisiran.
  3. Single-Disease Focus Studies:
    Research focusing solely on single cardiovascular diseases without considering comorbidities is becoming less frequent, as the field increasingly recognizes the importance of a multimorbid perspective.

Similar Journals

SCANDINAVIAN CARDIOVASCULAR JOURNAL

Fostering collaboration for a healthier cardiovascular future.
Publisher: TAYLOR & FRANCIS LTDISSN: 1401-7431Frequency: 6 issues/year

The Scandinavian Cardiovascular Journal, published by Taylor & Francis Ltd, is a distinguished peer-reviewed journal aimed at advancing the field of cardiology and cardiovascular medicine. With an impressive history dating back to 1967 and a forward-looking perspective until 2024, it has consistently contributed valuable research and insights, making it essential reading for anyone involved in cardiovascular healthcare. The journal holds a strong position in the academic community, reflected in its Q2 rating in both Cardiology and Cardiovascular Medicine, and a similar classification in the broader field of Medicine as of 2023. It is indexed in multiple databases, with a Scopus rank of #178 out of 387 in its category, placing it in the 54th percentile. The journal provides open access options, promoting wider dissemination of knowledge while supporting both researchers and practitioners dedicated to improving cardiovascular health. Its focus on high-quality, impactful research makes it an invaluable resource for professionals and students alike, keen to stay at the forefront of cardiology advancements.

CARDIOLOGY CLINICS

Advancing cardiovascular knowledge for a healthier tomorrow.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0733-8651Frequency: 4 issues/year

CARDIOLOGY CLINICS is a prestigious journal published by W B SAUNDERS CO-ELSEVIER INC, offering insightful and comprehensive reviews in the field of cardiology and cardiovascular medicine since its inception in 1983. With its ISSN 0733-8651 and E-ISSN 1558-2264, the journal has established a significant impact factor within the academic community, holding a Q2 ranking in both Cardiology and Cardiovascular Medicine as well as in Medicine (miscellaneous) for 2023. Located in the heart of Philadelphia, USA, it serves as a vital resource for researchers, clinicians, and students seeking to deepen their understanding of cardiovascular diseases and advancements in treatment. Although it operates under a traditional subscription model, the journal remains committed to disseminating valuable knowledge that shapes current practices and informs future research directions. As it converges towards its 2024 issues, CARDIOLOGY CLINICS continues to play an influential role in enhancing the discourse on cardiovascular health worldwide, ensuring that its audience stays at the forefront of clinical and scientific developments.

VASCULAR PHARMACOLOGY

Pioneering research for a healthier vascular future.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Cardiology Research and Practice

Exploring breakthroughs in heart health and treatment.
Publisher: HINDAWI LTDISSN: 2090-8016Frequency: 1 issue/year

Cardiology Research and Practice is a leading academic journal dedicated to advancing knowledge in the fields of cardiology and cardiovascular medicine. Published by HINDAWI LTD, this journal has been an inclusive platform for open access research since 2009, facilitating the dissemination of high-quality studies that contribute to the global scientific community. With an impact factor placing it in Q2 of its category in 2023, it underscores its importance in delivering innovative insights and discoveries that shape clinical practices and policies. The journal covers a broad scope of topics including, but not limited to, cardiovascular disease prevention, innovative treatment modalities, and emerging technologies, appealing to researchers, healthcare professionals, and students alike. Located in the United States with its international reach, Cardiology Research and Practice serves as a critical resource for those dedicated to improving patient outcomes and advancing the field of cardiology.

Expert Review of Cardiovascular Therapy

Connecting Theory and Practice in Cardiovascular Therapy
Publisher: TAYLOR & FRANCIS INCISSN: 1477-9072Frequency: 12 issues/year

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

Netherlands Heart Journal

Bridging Research and Practice in the World of Cardiovascular Medicine
Publisher: BOHN STAFLEU VAN LOGHUM BVISSN: 1568-5888Frequency: 12 issues/year

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Anatolian Journal of Cardiology

Fostering Cardiovascular Excellence Since 2001.
Publisher: KARE PUBLISSN: 2149-2263Frequency: 12 issues/year

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.

KARDIOLOGIYA

Empowering the Future of Heart Disease Management
Publisher: RUSSIAN HEART FAILURE SOCISSN: 0022-9040Frequency: 12 issues/year

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Heart International

Exploring innovative insights in cardiology and cardiovascular medicine.
Publisher: TOUCH MEDICAL MEDIA LTDISSN: 2036-2579Frequency: 2 issues/year

Heart International is a prominent open-access journal dedicated to the fields of cardiology and cardiovascular medicine, published by TOUCH MEDICAL MEDIA LTD since 2006. Based in Italy, this journal serves as a vital platform for researchers, clinicians, and students, aiming to disseminate cutting-edge scientific findings and clinical insights that advance the understanding of heart health. With an ISSN of 2036-2579 and an emphasis on accessible content, Heart International ensures that valuable research is available to a wide audience, thereby contributing to the global discourse on cardiovascular issues. Although it currently holds a Q4 quartile ranking in its category and is positioned in the lower percentile for Scopus rankings, the journal is committed to improving its impact through rigorous peer review and high-quality publications. The journal covers a wide array of topics within the cardiology domain, making it an essential resource for those looking to stay abreast of the latest developments in heart research.

CARDIOVASCULAR DRUGS AND THERAPY

Championing breakthroughs in heart health solutions.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.